Cendakimab

Last updated

Cendakimab
Monoclonal antibody
Type ?
Target Interleukin 13
Clinical data
Other namesRPC4046; ABT 308; CC-93538
ATC code
  • None
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG

Cendakimab (RPC4046; ABT 308; CC-93538) is a monoclonal antibody against interleukin 13. It is developed by Bristol Myers Squibb [1] for eosinophilic esophagitis. [2] [3] [4]

References

  1. ↑ "Pharmaceutical Research & Development Pipeline - Bristol Myers Squibb". www.bms.com. Retrieved 4 December 2023.
  2. ↑ Syverson EP, Hait E (April 2022). "Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis". Gastroenterology & Hepatology. 18 (4): 207–212. ISSN   1554-7914. PMC   9053490 . PMID   35505944.
  3. ↑ Caldwell J, Ballaban A, Li J, Maddux R, Harris S, Rothenberg M (February 2023). "Anti–IL-13 (cendakimab) administration improves esophageal gene expression in eosinophilic esophagitis". Journal of Allergy and Clinical Immunology. 151 (2): AB215. doi:10.1016/j.jaci.2022.12.670. S2CID   256589074.
  4. ↑ Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. (February 2019). "RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis". Gastroenterology. 156 (3): 592–603.e10. doi: 10.1053/j.gastro.2018.10.051 . PMID   30395812.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.